Impact of Blood Phobia on Fainting Susceptibility

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorSimon Fraser University

About this trial

The primary purpose of this study is to characterize cardiovascular autonomic function to emotional stimuli (blood-injection-injury phobia \[needle phobia\]) during an orthostatic (upright) challenge in individuals with and without known needle phobia. It is well established that emotional stress can produce hypotensive (low blood pressure) reactions. Interestingly, these hypotensive reactions to venipuncture (even with minimal blood drawn), insulin injections, finger sticks for blood sugar monitoring, dental care, and vaccinations can affect up to a quarter of adults and appear to be uniquely associated with blood-injection-injury phobia rather than other phobias. These hypotensive reactions can ultimately lead to a vasovagal syncope (fainting) response, and lead to increased avoidance of medical and dental procedures as a result of this phobia. Ultimately, this has severe implications on public health and places additional strain on the Canadian healthcare system. Currently, there is limited understanding surrounding the initiation of this response. Additionally, a comprehensive profile of cardiovascular autonomic function during exposure to provoking stimuli during orthostatic stress has not been captured in the literature. We will test individuals with and without blood-injection-injury phobia using our standard approach while exposing them to emotional stimuli.

Eligibility criteria

Qualifiers

male and female

18 to 50 years old

those without a suspected BII fear and those with a suspected fear

english speaking

Disqualifiers

diagnosis of any cardiovacular or neurological disorder

menopausal

taking medication for a cardiovascular condition

if they are pregnant

Trial design

Treatments tested in this trial

  • blood-injection-injury (BII) phobia stimuli
  • neutral stimuli

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators